AstraZeneca Announced Saturday, IMFINZI Plus Tarlatamab-dlle Cuts Death Risk 58% Versus IMFINZI Alone In First-Line Extensive-Stage Small Cell Lung Cancer, Median OS 21.1 Versus 12.7 Months, In DeLLphi-305 Phase III
Benzinga Newsdesk 1 week ago
News
Novel combination demonstrated a median overall survival of nearly two years, the longest benefit ever reported in extensive stage disease in a Phase III trialResults reinforce IMFINZI as the backbone immunotherapy
Novel combination demonstrated a median overall survival of nearly two years, the longest benefit ever reported in extensive stage disease in a Phase III trial
Results reinforce IMFINZI as the backbone immunotherapy across stages of small cell lung cancer